Occidental Petroleum OXY
Energy · Oil & Gas Exploration & Production · Synthos Deep Dive · 2026-07-03
The Overview
Occidental pumps oil and natural gas, mostly in Texas's Permian Basin, plus the Middle East and North Africa. It just sold its chemicals business (OxyChem) and is using the money to pay down a big pile of debt — it knocked debt down from over $20 billion toward a $10 billion goal.
Is the stock cheap or expensive? Cheap on the numbers — you pay under 12× earnings and about 5× cash profits, well below the market. But cheap-for-a-reason: an oil producer earns whatever the oil price lets it earn, and it can't make oil go up. When oil falls, so do the profits — and the debt gets scarier.
Our verdict is Watch: a fair-priced, financially-improving company with no real growth engine and a stock stuck in a downtrend. Own it only if you specifically want exposure to a higher oil price.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit above average). The stock barely moves with the market day-to-day (low beta), and it's cheap — but it's a boom-bust commodity business carrying real debt, and it's already fallen 36% from its high.
- Growth Quality 4/10 (below average). After selling chemicals the company gets smaller, and profits are expected to be flat or lower over the next few years unless oil rises.
- Exponential Potential 3/10 (low). This is a mature, steady business, not a fast grower. Its one "moonshot" — capturing carbon from the air — is real but years from mattering to the bottom line.
The one big worry: the oil price. Everything — the earnings, the dividend, the debt-paydown plan — rides on it, and Occidental has no control over it.
Putting a number on it: our fair-value estimate is $52 against a current price of $59.10 — a premium price for a business we still like.
Our summary metrics
Cheap (11.9× P/E, 5.3× EV/EBITDA) & low beta 0.12, but commodity-cyclical with $22B net debt and a −36% drawdown.
Post-OxyChem-sale the top line shrinks; flat-to-declining forward EPS ($5.60 FY26E → ~$3.97 FY30E), mid-single-digit ROIC.
A mature, price-taking E&P; no acceleration and no room-to-run multiple — the CCS optionality is real but distant and unproven.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, We don’t publish a reverse-DCF cross-check for pre-profit companies — negative or missing earnings break that math — so take this number on our modeling alone.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
A mature, price-taking E&P; no acceleration and no room-to-run multiple — the CCS optionality is real but distant and unproven.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $63.46 (high $75 / low $45; 25 Buy · 23 Hold · 4 Sell) — context, not our anchor |
| Valuation | 11.9× trailing EPS · ~8.7× FY26E · EV/EBITDA 5.3× · EV/S 2.6× · P/B 1.2× · FCF yield ~7.3% |
| Technicals | Downtrend — $48.91, −26% off 52-wk high, below 50/200-DMA, RSI 22 (oversold), +14% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices in KB; call rests entirely on fundamentals + quant |
| Position sizing | Satellite/value-cyclical only, ≤2%, and only if you want oil-price beta |
What the experts actually said 4 traceable claims on OXY · showing the highest-conviction voices
“Holds a position (via Occidental thesis) betting oil goes a lot higher, driven by years of underinvestment in expanding production capacity as companies bought back shares instead.”
“Long-term bullish on Occidental as part of an energy sector in the early innings of a 5-10 year story.”
“Buffett's Chevron and Oxy bets make sense at his scale — Oxy for its oil-price torque — but diseconomies of scale mean the majors don't obviously deserve a much higher valuation.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $59.10, 7% above the 50-day average ($55), 14% above the 200-day average ($52) — an uptrend. 11% below the 52-week high of $66, 52% above the 52-week low of $39.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $59.10 is currently inside the band (band $54–$62).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 55.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.15, negative momentum.
Relative performance vs S&P 500 & its sector (XLE (sector)), set to 100 a year ago
Solid = OXY · dashed = S&P 500 · dotted = XLE (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Occidental Petroleum (NYSE: OXY) is an ~$49B international energy company founded in 1920 and headquartered in Houston, led by President & CEO Richard Jackson (long-time CEO Vicki Hollub now sits on the board). It explores for, develops and produces oil, natural gas liquids (NGLs) and natural gas, concentrated in the Permian Basin, the Rockies, the Gulf of America, and the Middle East/North Africa, plus a midstream & marketing arm and a carbon-management/CCS business (1PointFive / Stratos direct-air-capture). Fiscal year ends December 31.
The defining recent event: Occidental sold OxyChem, its chemicals segment, closing in Q1'26. That divestiture drives most of the optics in the numbers below — it shows up as a $3.1B gain in discontinued operations in Q1'26 and is why the chemical segment vanishes from the FY2025 product mix and reported revenue steps down. The strategic point of the sale was debt reduction (see §9).
Revenue mix (FY2025, from filings — continuing operations):
- By segment: Oil & Gas $20.90B (94%) · Midstream & Marketing $1.26B. (Chemical Segment was $4.92B in FY2024 and is now gone via the OxyChem sale.)
- By geography (Oil & Gas): United States $20.83B · Non-US $4.13B. The production base is US-weighted (Permian core) with a strategically important Middle East/North Africa contribution (e.g. Al Hosn in the UAE).
This is a price-taking commodity producer: it does not set the price of its product. That single fact frames every score below.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of OXY in the Synthos knowledge base. total_claims = 0; there are zero net-bullish and zero cautionary voices. We therefore make no claim of expert conviction, and there are no claim_id values to cite. This entire note is fundamentals- and quant-driven — built from FMP financials, analyst consensus estimates (labeled as estimates), the SEC 8-K earnings release, and our own scoring model.
Honesty note: OXY is famously a large Berkshire Hathaway holding, but that is not in our data set, so we do not lean on it as a thesis pillar — we flag it only as context an investor should independently verify.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Above-avg | Genuinely cheap (11.9× P/E, 5.3× EV/EBITDA) and low reported beta (0.12), which cushions day-to-day — but this is a commodity-cyclical with $22.0B net debt (net-debt/EBITDA ~1.0×), a −36% max drawdown, and earnings that live or die on the oil price. Cheapness offsets, but does not erase, the cyclicality. |
| Growth Quality | 4 · Below-avg | Post-OxyChem the company shrinks: reported revenue $27.1B (FY24) → $21.6B (FY25), and consensus EPS is flat-to-declining ($5.60 FY26E → ~$3.99 FY27E → ~$3.97 FY30E). ROIC ~2.6% TTM, ROE ~12.8%. Margins are respectable (EBITDA ~49% TTM) but the durability is commodity-dependent, not franchise-driven. |
| Exponential Potential | 3 · Low | A mature, capital-intensive E&P. No forward acceleration (growth is negative-to-flat), and at ~$49B it has no "small-cap room-to-run" multiple. The CCS/direct-air-capture optionality (Stratos) is real but distant, subsidy-dependent and unproven at scale. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities. The cases bound the range, and the scores above summarize them. Note the estimate set is messy because analyst EPS lines straddle the OxyChem divestiture — so we anchor the bull/bear on oil price and EV/EBITDA, the honest drivers of an E&P, rather than a single EPS number.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | WTI sustains ~$80+; production grows off the high end of guidance (Q1'26 already beat at 1,426 Mboed); deleveraging hits the $10B goal and frees cash for buybacks; CCS gains credibility. EV/EBITDA re-rates to ~6.5× on ~$13B EBITDA. | ~$74 (+51%) |
| Base (our anchor) | WTI ~$70–75; EBITDA ~$11.5–12B (roughly the FY30E consensus zone); debt paydown continues; multiple holds ~5.5× EV/EBITDA. Modest re-rate as the balance sheet de-risks. | ~$52 (+6%) |
| Bear | WTI slips toward $55–60; EBITDA compresses; deleveraging stalls and the market re-prices the cyclicality; multiple de-rates to ~4.5×. | ~$34 (−30%) |
Synthos fair value = the base case, ~$52 (+6%), with the full $34–$74 span as the honest range. Our base sits below the Street's $63.46 consensus because we underwrite a more neutral oil deck and give less credit to a re-rating; our bull roughly meets the Street's $75 high. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). OXY is neither — it is a mature cyclical:
- Forward growth: revenue is shrinking post-OxyChem; consensus revenue drifts ~$25.9B (FY26E) → ~$24.0B (FY30E). EPS consensus is flat-to-down: $5.60 (FY26E) → ~$3.99 (FY27E) → ~$3.97 (FY30E). There is no forward EPS CAGR to speak of — arguably a mild decline.
- Acceleration (2nd derivative): negative/flat. This is the opposite of an exponential; the business is ex-growth on flat commodity prices, with volume growth (guidance beats) offset by price and the loss of the chemicals earnings stream.
- Room to run: at ~$49B market cap in a mature, well-supplied oil market, there is no structural TAM-expansion story to power a multibagger. The equity's upside is a higher oil price and a cleaner balance sheet, not a new S-curve.
- The one optionality: carbon capture / direct air capture (1PointFive, the Stratos DAC facility). Genuinely differentiated and management leans on it, but it is subsidy- and policy-dependent, years from moving consolidated earnings, and not in any expert or estimate line we can verify. Treat it as a call option, not a base-case driver.
Exponential Potential: Low (3/10). Own OXY, if at all, for cheap cyclical value and oil-price beta — not for compounding or a moonshot.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $21.59B (continuing-ops basis) vs FY24 $27.10B and FY23 $28.33B — the step-down reflects the OxyChem divestiture and softer commodity prices. The 2022 peak was $36.25B (the energy-price spike year).
- Quarterly trajectory: Q1'25 $6.80B → Q2 $6.32B → Q3 $6.62B → Q4 $5.01B → Q1'26 $5.23B. Revenue is a function of the oil price, not a growth ramp.
- Margins: gross ~26% TTM, EBITDA ~49% TTM (capital-intensive E&P economics — high EBITDA, heavy D&A), net ~20% TTM. Operating income $3.72B FY25.
- Earnings: net income $2.37B FY25 (EPS $1.69, diluted $1.61) vs $3.04B FY24. Q1'26 reported EPS was $3.13 — but that is flattered by the $3.1B OxyChem gain in discontinued operations; adjusted EPS from continuing operations was $1.06 (management's own figure, §9). Use the adjusted number.
- Cash flow: operating CF $10.53B, capex −$6.43B, FCF ~$4.1B FY25 (FCF yield ~7.3%). Capex/OCF ~63% — this is a capital-hungry business that must keep drilling to hold production flat.
- Balance sheet: total debt $23.96B, cash $1.99B, net debt $22.0B, net-debt/EBITDA ~1.0× TTM. Aggressive deleveraging in progress (§9): management says it repaid $7.1B of principal through May 5, cutting principal debt to $13.3B and targeting a $10.0B milestone. Preferred stock $8.29B sits above the common (the Berkshire preferred).
6. Valuation — priced in or room?
On the surface OXY is cheap: 11.9× trailing EPS, ~8.7× FY26E, 5.3× EV/EBITDA, 2.6× EV/sales, 1.2× book, ~7.3% FCF yield, and FMP's letter rating is A−. For an energy name those are undemanding multiples. The honest caveats:
1. Cheap multiples are normal for E&Ps — the market structurally pays low multiples for price-taking, cyclical, capital-intensive commodity earnings. 5–6× EV/EBITDA is a sector-typical number, not a screaming discount.
2. The "E" is unstable. Forward EPS is flat-to-down and swings with oil; a low P/E on a mid-cycle-or-better earnings level is a trap if oil rolls over.
3. The equity is levered to oil through $22B of net debt plus $8.3B of preferred ahead of it, which amplifies both directions.
Street targets (context): consensus $63.46, high $75, low $45; grades 25 Buy / 23 Hold / 4 Sell ("Buy" but with a heavy Hold contingent). Our ~$52 base is deliberately below consensus — we won't underwrite a bullish oil deck we can't verify. Verdict on valuation: fairly-to-cheaply priced for what it is, but "cheap" here is compensation for cyclicality, not a mispricing to pound the table on.
7. Technicals (from the tech block)
- Trend: down. $48.91 sits below the 50-DMA ($55.98) and 200-DMA ($49.37), and the 50 is below the 200 posture is deteriorating. MACD −2.31 (negative).
- Location: −26.2% off the 52-week high ($66.24), +25.7% off the 52-week low ($38.92); max drawdown −35.6% from peak — a meaningful decline.
- Momentum: RSI(14) 22 — oversold (<30). That flags a possible near-term bounce/mean-reversion, but oversold in a downtrend is not by itself a buy signal.
- Relative strength (the tell): OXY −21.4% over 3 months while SPY +13.7% and QQQ +22.0% — sharp underperformance recently; +14.1% 12-mo vs SPY +20.6%. It has lagged both the market and tech badly this quarter.
- Read: technicals are bearish but stretched. The oversold RSI could produce a tactical bounce, but the primary trend is down and price is fighting both moving averages. No technical confirmation for a durable long here — which reinforces the Watch, not Buy.
8. Moat & competitive position
Occidental's edge is asset quality and scale in the Permian, a low-cost midstream footprint, and a genuinely differentiated carbon-management franchise (direct air capture) that no major peer matches at the same commitment level. But an E&P's "moat" is fundamentally shallow: it sells an undifferentiated commodity at a price it does not control. Cost position and inventory depth matter, brand and switching costs do not. Management's own framing (§9) — "the most resilient, competitive, and high-quality portfolio in our history" — is a low-cost-and-long-life argument, not a pricing-power one.
Peer set (market cap, from data): Diamondback Energy $48.4B (closest E&P comp), Baker Hughes $52.4B, EQT $32.9B, Energy Transfer $66.5B, Imperial Oil $56.6B, Cheniere $51.5B, ONEOK $55.3B, Suncor $65.0B, Targa $55.6B, Woodside $37.0B. Several of these are midstream/services (more stable, less oil-price-levered); the pure-E&P comp (FANG) trades on similar cyclical logic.
9. Management, capital allocation & guidance
- Capital allocation: the current story is deleveraging above all. Post-OxyChem cash is going to debt paydown rather than buybacks, and FY25 FCF (~$4.1B) covered the dividend (~$1.6B paid) with room. A disciplined, balance-sheet-first posture — appropriate given the cyclicality.
- Insider activity (a real positive signal): President & CEO Richard Jackson made an open-market purchase of 4,770 shares at $52.38 on 2026-06-23 (Form 4 filed 2026-06-24). Open-market buying by the CEO — as opposed to routine award/withholding activity — is a genuine, if small, vote of confidence. Other recent filings (Hollub, directors) are routine equity awards and in-kind tax withholding, not discretionary selling.
- Management's own guidance (half-weighted — their own self-interested words). From the SEC 8-K / Q1'26 earnings release (filed 2026-05-05), management's own statements: total company production of 1,426 Mboed exceeded the high end of guidance; midstream & marketing pre-tax adjusted income exceeded the high end of guidance; they repaid $7.1B of principal debt through May 5, cutting principal debt to $13.3B and progressing toward a $10.0B milestone; Q1 generated $1.4B operating cash flow ($3.2B before working capital) and $1.7B free cash flow before working capital; adjusted EPS from continuing operations was $1.06 (vs the $3.13 reported, which included the OxyChem gain). Q1 realized crude ~$69.91/bbl (+18% q/q). Treat these as management's book — directionally useful, half-weighted.
10. Catalysts & what to watch
- Next earnings: 2026-08-05 (Q2'26; Street EPS $1.85, revenue ~$7.2B). Watch realized oil price, production vs guidance, and the debt balance vs the $10B target.
- The oil price itself — WTI/Brent are the dominant swing factor for every line.
- Deleveraging milestone: progress toward $10B principal debt; hitting it could unlock a shift back toward buybacks (a re-rating catalyst).
- CCS/DAC (Stratos / 1PointFive): any commercial validation, offtake, or policy/subsidy news on direct air capture.
- Capital-return pivot: the first sign management shifts from debt paydown to shareholder returns.
Thesis tripwires (what would change the call): a sustained WTI break below ~$60 (bearish); hitting the $10B debt goal and restarting buybacks (bullish, would push toward Buy — Tactical); or a production/cost miss that breaks the low-cost-portfolio narrative.
11. Key risks
- Oil price (the master risk): revenue, EPS, FCF and the deleveraging plan all move directly with WTI/Brent, which Occidental cannot control.
- Leverage into a cyclical: $22.0B net debt plus $8.3B preferred ahead of the common amplifies downside if oil falls before the balance sheet is fully repaired.
- Post-divestiture shrinkage: with OxyChem sold, the earnings base is smaller and more concentrated in commodity oil & gas — less diversification, not more.
- Secular energy-transition overhang: long-run demand and policy risk for hydrocarbons; the CCS bet is a hedge but is itself policy/subsidy-dependent.
- Technical downtrend: price below both moving averages and −36% off the high signals the market is not yet convinced.
- No expert corroboration: zero Synthos KB coverage — we cannot triangulate this call against independent expert conviction, so it rests on quant/fundamentals alone.
12. Verdict, position sizing & monitoring
Watch. OXY is a cheap (11.9× EPS, 5.3× EV/EBITDA), low-beta, aggressively-deleveraging Permian oil producer with a CEO buying his own stock and a credible balance-sheet-repair story — but it is fundamentally a price-taking commodity business whose forward earnings are flat-to-declining, whose stock is in a technical downtrend, and whose entire equity thesis reduces to a levered bet on the oil price. That is a Watch, not a Buy: fairly valued for what it is, with the upside gated by a commodity nobody controls and by a re-rating we won't pre-underwrite.
- Sizing: if owned at all, a satellite/value-cyclical position ≤2%, sized as deliberate oil-price exposure — not a core compounder. A tactical entry is more defensible on the oversold RSI if oil firms and the downtrend breaks.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print and on any $10B-debt-milestone / buyback-restart news (which could move this to Buy — Tactical). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $48.91.
- Single biggest risk: the oil price — everything rides on it.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of OXY in the Synthos knowledge base, so no
claim_idvalues are cited and no expert conviction is claimed. This note is fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation). - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K earnings release filed 2026-05-05. Forward figures are analyst consensus (FMP), labeled as estimates; note the estimate set straddles the OxyChem divestiture and is noisy.
- Management caveat: the §9 guidance is management's own self-interested words, half-weighted by design.
- Context flagged, not relied upon: OXY's well-known Berkshire Hathaway ownership is not in our data set and is not used as a thesis pillar.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").